<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="155769">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01071993</url>
  </required_header>
  <id_info>
    <org_study_id>15097</org_study_id>
    <nct_id>NCT01071993</nct_id>
  </id_info>
  <brief_title>Efficacy of Statins In Prevention of CIN</brief_title>
  <acronym>SCIN</acronym>
  <official_title>Efficacy Of Statins In The Prevention of Contrast-Induced Nephropathy in Patients With Chronic Renal Insufficiency (SCIN Trial): A Double-Blind, Placebo-Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oklahoma</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Oklahoma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine if statin therapy plus intravenous normal saline, in patients with chronic
      renal insufficiency undergoing angiography, is superior to placebo plus intravenous normal
      saline therapy in the prevention of CIN.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Due to the conflict in the available data, there are no practice guidelines that are
      established in order to prevent contrast-induced nephropathy (CIN). Our goal is to determine
      if statin therapy plus intravenous normal saline, in patients with chronic renal
      insufficiency undergoing angiography, is superior to placebo plus intravenous normal saline
      therapy in the prevention of CIN.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Sponsor can not supply drugs anymore
  </why_stopped>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary endpoint. Development of CIN (contrast-induced nephropathy) defined as a postprocedure increase in serum creatinine of &gt; 0.5 mg/dL or &gt;25% increase from baseline at 24 &amp; at 48 hours.</measure>
    <time_frame>48 hours</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Nephropathy</condition>
  <arm_group>
    <arm_group_label>atorvastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>pre-treatment with placebo (80 mg 12 hours prior to the procedure and 40 mg pre-procedure)</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>atorvastatin</intervention_name>
    <description>pre-treatment with atorvastatin (80 mg 12 hours prior to the procedure and 40 mg pre-procedure)</description>
    <arm_group_label>atorvastatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        1. Inclusion Criteria:

               -  Adults &gt; 18 years of age

               -  undergoing coronary or peripheral angiography with or without intervention

               -  Cr &gt; 1.3 mg/dL or GFR &lt; 60 mL/min

          2. Exclusion Criteria:

               -  end-stage renal disease on dialysis

               -  acute renal failure

               -  previous iodinated contrast media exposure within 7 days of study entry

               -  history of hypersensitivity to statins

               -  pregnancy or lactation

               -  emergent coronary angiography, ST elevation myocardial infarction (STEMI), or
                  cardiogenic shock

               -  prisoners

               -  patients already on maximum dose of statins

               -  patient receiving N-acetylcysteine or sodium bicarbonate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mazen Abu-Fadel, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oklahoma Univeristy Health Science Center and VA Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oklahoma University Health Science Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veterans Affairs Medical Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 13, 2014</lastchanged_date>
  <firstreceived_date>February 18, 2010</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>prevention</keyword>
  <keyword>nephropathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Kidney Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
